WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that the American Association of Cancer Research (AACR) highlighted data at a press conference in Washington, D.C. from a clinical trial evaluating a novel combination regimen of two of the Company's orally available, experimental drugs, sapacitabine and seliciclib. The trial enrolled patients with an incurable form of cancer associated with BRCA defects in the patients' genome. The press conference was held yesterday on the occasion of the American Association of Cancer Research (AACR) Annual Meeting 2013 which opened here this weekend.
"We are pleased to have our data with sapacitabine and seliciclib selected by the AACR's Annual Meeting Program Committee," said Spiro Rombotis, Cyclacel's President and Chief Executive Officer. "Our novel, all-oral, combination of two Cyclacel drugs fits the theme of this year's AACR: ' Personalizing Cancer Care Through Discovery Science'. This recognition of the importance of our work attests to the quality of Cyclacel's scientists and pipeline. Together with our late-stage clinical trial of sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia, these promising data in patients with solid tumors suggest the emergence of a personalized medicine strategy for Cyclacel in an area of high unmet medical need."
The press conference highlighted a small number of data presentations selected from approximately 6,000 scientific presentations at the conference by investigators from around the globe. Among the selected data, AACR previewed promising results of the sapacitabine and seliciclib regimen. The regimen was used to treat patients with incurable BRCA-deficient cancers. There are no drugs yet approved specifically for this patient population.At the press conference the principal investigator of the study, Geoffrey Shapiro, M.D., Director, Early Drug Development Center, Dana-Farber Cancer Institute and Associate Professor, Department of Medicine, Harvard Medical School, announced that when given sequentially, sapacitabine and seliciclib, worked together to induce durable partial responses and prolonged stable disease in patients who carry a BRCA mutation. The complete data will be formally presented by Dr. Shapiro during the scientific session of the AACR on Tuesday, April 9, at 2 pm Eastern.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts